Design Therapeutics, Inc. (DSGN) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DSGN Hot Sheet
Join SI Premium – FREE
Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q3 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Matrix Service (MTRX) Tops Q1 EPS by 5c
- Northwest Natural Gas (NWN) Tops Q3 EPS by 18c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
